Table 2.
Characteristics and outcome of COVID-19 in patients treated with chemoimmunotherapy
| Total number of patients | 34 |
| Age at CLL diagnosis, median (range) | 67 (49–81) |
| Age at COVID-19 diagnosis, median (range) | 72 (52–82) |
| Male, n (%) | 25 (74) |
| Unmutated IGHV, n (%)* | 18 (67) |
| Mutated TP53 and/or deleted 17p† | 0 (0) |
| Obesity, n (%)‡ | 11 (32) |
| Hypogammaglobulinemia, n (%)§ | 13 (38) |
| Major comorbidities, n (%) | 30 (88) |
| Chemoimmunotherapy regimen at COVID-19 diagnosis | |
| BR, n (%) | 21 (62) |
| FCR, n (%) | 5 (15) |
| G-Clb, n (%) | 4 (12) |
| RCD, n (%) | 3 (9) |
| R-Clb, n (%) | 1 (3) |
| Vaccination prior to SARS-CoV-2 infection, n (%) | 0 (0) |
| Previous lines of therapy for CLL, median (range) | 1 (1–4) |
| COVID-19 course and outcome | |
| Hospitalization, n (%) | 28 (82) |
| ICU Admission, n (%) | 11 (32) |
| Deaths, n (%) | 17 (50) |
*IGHV available in 27 pts; †TP53 status available in 30 pts; ‡obesity defined as body mass index (BMI) ≥ 30; §data available in 32 pts; abbreviations: n, number of patients; CLL, chronic lymphocytic leukemia; IGHV immunoglobulin heavy chain variable region; TP53, tumour protein p53; BR, bendamustine and rituximab; FCR, rituximab, fludarabine and cyclophosphamide; G-Clb, obinutuzumab and chlorambucil; RCD, rituximab, cyclophosphamide, and dexamethasone; R-Clb, rituximab, and chlorambucil